Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease

Heiligenhaus, Arnd; Thurau, Stephan; Hennig, Maren; Grajewski, Rafael S.; Wildner, Gerhild

doi:10.1007/s00417-010-1485-8

Cited by 48 publications

(35 citation statements)

References 192 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 Our study focused on the possibility that interleukin-6 (IL-6) directly stimulates VEGF and angiogenesis. 21,22 Elevated IL-6 levels have been reported in retinal and iris neovascularization patients. 23 With the realization that IL-6 secretion may underlie some instances of pathological ocular vasopermeability and angiogenesis, we were interested in determining whether existing therapies, such as bevacizumab, had any beneficial effects in countering this pathology.…”

mentioning

confidence: 98%

“…Tocilizumab, recently used for rheumatoid diseases, suppresses the action of IL-6 by competing with it and affecting its receptor. 21,22,26 Tocilizumab has already been used intravenously to treat uveitis because of its antiinflammatory action. 27,28 However, there have been no previous studies on the antiangiogenic effect of tocilizumab after subconjunctival administration in vivo.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effects of Subconjunctival Tocilizumab Versus Bevacizumab in Treatment of Corneal Neovascularization in Rabbits

Yoo

Chung

2014

Cornea

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 98%

mentioning

confidence: 99%

Effects of Subconjunctival Tocilizumab Versus Bevacizumab in Treatment of Corneal Neovascularization in Rabbits

Yoo

Chung

2014

Cornea

View full text Add to dashboard Cite

show abstract

“…Interim analysis of an ongoing randomized controlled trial revealed a significant reduction in the recurrence rate of attacks during adalimumab treatment, even in patients with a high recurrence rate [45]. Results from trials of etanercept are more contradictory [46]. Psoriasis patients react well to infliximab, etanercept, and adalimumab.…”

Section: Tumor Necrosis Factor-α Blockadementioning

confidence: 97%

Mucosal Inflammation in Spondylarthritides: Past, Present, and Future

et al. 2011

View full text Add to dashboard Cite

Spondylarthritides (SpA) and inflammatory bowel disease (IBD) are idiopathic, chronic inflammatory disorders. Although they are very distinct and well-defined entities, there is clinical and genetic evidence supporting some degree of overlap between the pathogenesis of the two. Subclinical gut inflammation is present in up to two thirds of all SpA patients and can evolve into IBD. This subclinical gut inflammation has been shown to be strongly associated with joint inflammation, providing a clue for a common pathophysiologic background. Despite extensive research progress in the field over the past few years, many questions remain unanswered. In this paper, we focus on the clinical, genetic, and pathophysiologic overlap of SpA and IBD. Furthermore, we discuss some of the targets that may influence therapeutic decision making.

show abstract

“…Sirolimus has been previously approved for the prevention of solid organ transplant rejection [69]. It binds to the FK binding protein-12 and inhibits a multifunctional serine-threonine kinase, the mammalian target of rapamycin (mTOR) [70].…”

Section: Sirolimusmentioning

confidence: 99%

Novel Therapies in Development for Diabetic Macular Edema

et al. 2015

View full text Add to dashboard Cite

Diabetic macular edema (DME) secondary to diabetic retinopathy (DR) is a major cause for functional visual loss in the developed world. Laser photocoagulation has been used for decades in the treatment of DME. However, the advent of anti-vascular endothelial growth factor (anti-VEGF) has revolutionized the treatment of DME. Three important anti-VEGF agents whose efficacy has been well established via phase III clinical trials include ranibizumab, bevacizumab, and aflibercept. However, even in the era of anti-VEGF therapies, there are some challenges that retina specialists have to confront in managing patients with DME. These include the need for frequent treatment and an unpredictable response to therapy. There is evidence to suggest that pathways other than the VEGF pathway may be playing a role in the development of DME. Thus, extensive research is focused on development of novel agents that target these pathways. This review focuses on novel therapeutic agents in development, which may be used as a monotherapy or in combination with anti-VEGF agents, for the management of DME in the future.

show abstract

Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease

Cited by 48 publications

References 192 publications

Effects of Subconjunctival Tocilizumab Versus Bevacizumab in Treatment of Corneal Neovascularization in Rabbits

Effects of Subconjunctival Tocilizumab Versus Bevacizumab in Treatment of Corneal Neovascularization in Rabbits

Mucosal Inflammation in Spondylarthritides: Past, Present, and Future

Novel Therapies in Development for Diabetic Macular Edema

Contact Info

Product

Resources

About